Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if giving tipifarnib after standard treatment will
prevent leukemia from coming back (relapsing). Tipifarnib belongs to a class of drugs called
Farnesyl Transferase Inhibitors (FTI). It blocks proteins that make leukemia cells grow.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.